Compare HNST & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNST | BLSM |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.4M | 483.4M |
| IPO Year | 2021 | 2026 |
| Metric | HNST | BLSM |
|---|---|---|
| Price | $4.76 | $13.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $5.20 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 1.8M | 131.5K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $371,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.17 | N/A |
| P/E Ratio | $49.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.07 | $11.22 |
| 52 Week High | $6.01 | $27.99 |
| Indicator | HNST | BLSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 42.76 |
| Support Level | $3.55 | $12.93 |
| Resistance Level | $5.72 | $17.53 |
| Average True Range (ATR) | 0.25 | 1.66 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 55.32 | 44.62 |
The Honest Co Inc is a personal care company dedicated to creating cleanly-formulated and sustainably-designed products for everyone from babies to adults. By combining thoughtful design with science-based innovation, the company delivers personal care products for everyone from babies to adults, spanning categories across wipes, personal care, diapers, and beauty. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.